Your Psoriasis Flares Have a Genetic Cause Your Dermatologist Hasn't Mentioned

Filaggrin is a structural protein that holds your skin barrier together. It helps your outermost skin cells aggregate, form tight junctions, and prevent water loss. Without functional filaggrin, your skin becomes dry, fragile, and permeable.

FLG loss-of-function variants like R501X and 2282del4 are carried by roughly 10% of people with European ancestry, but much higher in those with eczema and psoriasis. These variants produce truncated, nonfunctional filaggrin. Your skin barrier is literally weakened at the cellular level, allowing irritants and pathogens to penetrate deeper and triggering immune activation.

You experience this as extreme dryness even with regular moisturizing, sensitivity to soaps and fragrances, and flares triggered by minor irritants that don’t affect others. Your skin feels raw and reactive. You may have a personal or family history of eczema even if your psoriasis is the dominant condition now.

Interleukin-4 is a signaling molecule that instructs your immune system to mount a Th2 response, the allergic and atopic pathway. IL-4 activates B cells to produce IgE antibodies and mast cells to release histamine. In normal amounts, this is protective. In excess, it drives eczema, allergic skin reactions, and can overlap with psoriasis.

IL4 variants shift roughly 30-35% of the population toward a Th2-dominant immune phenotype. Your immune system is genetically biased toward allergic inflammation, making you more prone to flares when exposed to allergens, stress, or infections that would barely affect others.

You notice this as skin that reacts to fragrances, dyes, and fabrics, coexisting allergies or asthma, and flares that follow upper respiratory infections or allergy season. Your skin feels itchy and inflamed rather than thick and scaly like classic psoriasis, or you have both presentations simultaneously.

Interleukin-13 is another Th2 cytokine, closely related to IL-4, that directly targets skin cells and increases IgE production and mast cell activity. IL-13 is a hallmark of allergic inflammation and is highly expressed in atopic dermatitis lesions.

IL13 variants, present in roughly 30-35% of people, amplify this allergic signaling cascade. Your skin cells respond more aggressively to allergens and irritants because your IL-13 signaling is genetically overactive.

You may have a strong personal history of allergies, asthma, or food sensitivities coexisting with your psoriasis. Your flares often include intense itching, oozing, or lichenification (thickened, cracked skin) in addition to plaques. You may react to soaps, detergents, or fabric softeners that others tolerate.

The vitamin D receptor is present on immune cells and skin cells. When vitamin D binds to VDR, it activates genes that promote regulatory T cells (Tregs), suppress Th17 cell differentiation, and reduce inflammation. VDR is essential for skin immune tolerance.

VDR variants like BsmI and FokI, present in roughly 30-50% of people, reduce receptor sensitivity or expression. Your skin cells and immune cells respond less effectively to vitamin D signaling, meaning even adequate vitamin D levels leave your immune system skewed toward inflammation.

You often have low to low-normal vitamin D despite supplementing, and your psoriasis typically worsens in winter or in northern climates with less UVB exposure. You may notice flares correlate with lower sun exposure. Standard topical treatments help temporarily, but seasonal recurrence is predictable.

TNF-alpha is a master pro-inflammatory cytokine. It activates immune cells, increases vascular permeability, amplifies the production of other inflammatory molecules, and drives systemic inflammation. TNF is central to psoriasis pathology and is the target of biologic medications.

The TNF -308G>A variant, carried by roughly 30% of people, increases TNF-alpha production from immune cells. Your baseline inflammatory state is genetically higher, meaning your skin flares more easily and your systemic inflammation is more pronounced.

You experience this as psoriasis that responds well initially to TNF inhibitors (like adalimumab or etanercept), but you may eventually lose response, develop other inflammatory conditions, or have flares that feel systemic rather than localized. You may also have joint involvement (psoriatic arthritis) or inflammatory bowel symptoms.

CTLA4 is a checkpoint molecule on regulatory T cells that tells other T cells to calm down, stop attacking, and restore tolerance. It’s your immune system’s braking mechanism. Without functional CTLA4 signaling, T cells remain hyperactivated and autoimmune responses escalate.

CTLA4 +49A>G variant, present in roughly 45% of people, reduces CTLA4 function and expression. Your immune system has impaired regulatory capacity, making it harder for your body to suppress autoreactive T cells and recover immune tolerance after a flare.

You notice this as psoriasis that flares intensely after stress, infections, or vaccinations, and takes longer to resolve without intervention. You may have other autoimmune features or a family history of multiple autoimmune conditions. Your flares feel like your immune system is in overdrive and won’t settle down.